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Purpose: Total knee arthroplasty (TKA) is a popular procedure in severe osteoarthritis. But perioperative bleeding
remains a problem. Floseal® is a mixture of thrombin and bovine gelatin which can benefit a lot on reducing
intraoperative and postoperative bleeding. However, there is no enough evidence judging its safety and efficiency.
So a meta-analysis is conducted by us to evaluate the efficacy and safety of a thrombin-based hemostatic agent
compared with conventional methods in TKA.
Method: Two independent reviewers selected literatures published before August 2014 from MEDLINE, Embase, and
The Cochrane Central Register of Controlled Trials. Other internet databases were also performed to identify trials
according to the Cochrane Collaboration guidelines. High-quality randomized controlled trials (RCTs), prospective
control trials (PCTs), and case controlled trials (CCTs) were selected. The meta-analysis was undertaken using RevMan
5.1 for Windows.
Results: Three RCTs, one PCT, and one CCT met the inclusion criteria. There were significant differences in hemoglobin
decline and calculated total blood loss between the Floseal® group and control group. There were no significant
differences in postoperative drainage volume, rate of transfusion requirement, incidence of wound infection, deep vein
thrombosis (DVT), and pulmonary embolism (PE) between treatment and control groups.
Conclusions: The present meta-analysis indicates that a thrombin-based hemostatic agent can reduce hemoglobin
decline and calculated total blood loss after TKA and is not related to adverse reactions or complications such as
wound infection, DVT, and PE.
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Total knee arthroplasty (TKA) has become a common
treatment for severe knee arthritis [1]. However, because
of extensive soft tissue dissection, long operative time,
and a large amount of bone cutting, patients undergoing
primary TKA are particularly prone to large intraopera-
tive and postoperative blood loss which may lead to
morbidity including pain, decrease range of motion, and
delayed recovery. Although various methods have been
taken by surgeons to reduce blood loss including electro-
coagulation, cell salvage, predonated autologous blood* Correspondence: 2008021123@tijmu.edu.cn
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unless otherwise stated.transfusion, hemostatic agents, erythropoietic agents, and
minimally invasive surgery, many patients still need blood
transfusion for significant blood loss [2]. Besides, fibrinoly-
sis reaction activated by surgical injury and ischemia re-
perfusion after tourniquet deflation contribute to the
blood loss [3,4].
Allogenic blood transfusion may be related to systemic
complications such as anaphylactic reaction, immuno-
logical rejection, hemolytic reaction, infectious disease,
and metabolic disorders prolonging the duration of
hospitalization and causing serious social economic bur-
den [5]. So it is crucial to minimize the bleeding and
transfusion requirements for the patients undergoing
TKA.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Search results and the selection procedure.
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http://www.josr-online.com/content/9/1/90Hemostatic agent Floseal® is a mixture of thrombin
and bovine gelatin [6] which can benefit a lot on redu-
cing intraoperative and postoperative bleeding and
transfusion requirements. Thrombin-based hemostatic
agents have come out nearly 15 years and were widely
used in surgical procedure including gynecology, general
surgery, and orthopedics which were still attracting the
attention and interest of multitudinous surgeons. Clapp
M [7] found Floseal® can achieve hemostasis during a











Kim 2012 [11] 97/99 72.7/70.1 NS 10 Asp
Francesco 2013 [9] 51/42 67.9/70.2 24/17 10 LM
Suarez 2014 [10] 56/52 65.9/65.1 20/21 10 Eno





NS 64/54 20 Wa
F Floseal®, C control, LMWH low molecular weight heparin, NS not stated.Testini M [8] considered that Floseal® was an effective
additional agent compared with conventional hemostatic
procedures in thyroid surgery. A number of clinical trials
have been made to evaluate the efficacy and safety of the
hemostatic matrix in primary TKA. However, some have
been criticized for poor designs, inaccurate evaluations,
inconclusive results, and short-term follow-ups. There-
fore, we conducted a meta-analysis, pooling the data
from randomized controlled trials (RCTs) and non-RCTs






irin or warfarin, NS RCT 6
WH 4,000 IU RCT 4
xaparin, NS RCT 6
xaparin 40 mg PCT 17
rfarin 5 mg CCT 18
Figure 2 Forest plot diagram showing the effect of Floseal® on hemoglobin drop.
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We conducted a meta-analysis to identify academic arti-
cles from electronic databases, including MEDLINE
(1966 to August 2014), Embase (1980 to August 2014),
and The Cochrane Central Register of Controlled Trials.
Other internet databases were also performed to identify
trials according to the Cochrane Collaboration guide-
lines. There were no language restrictions. The search
strategy is presented in Figure 1. It included only studies
conducted on human subjects. In addition, using the
Google search engine, the same search terms were
manually searched to find any further relevant studies
that may have been missed in the database search. We
used the following key words: “knee replacement OR
arthroplasty” and “thrombin” in combination with Bool-
ean operators AND or OR.
Selection criteria and quality assessment
We included all published RCTs and non-RCTs compar-
ing Floseal® with a control (placebo or nothing) in patients
undergoing primary TKA. The methodological quality of
the included studies was assessed by the review authors
using a modification of the generic evaluation tool used by
the Cochrane Bone, Joint and Muscle Trauma Group. To
provide a qualification of a bias risk, quality criteria in-





χ2 I2 (%) MD 95% CI P value
Cemented
prosthesis
3 10.31 81 −0.62 [−1.22,−0.03] 0.006
Total dose =
10 ml
3 3.03 34 −0.52 [−0.77,−0.26] 0.22
Duration of
drainage
3 3.03 34 −0.52
[−0.77,−0.26]
0.22concealment, (iii) blinding of participants and personnel,
(iv) blind outcome assessment, (v) incomplete outcome
data, (vi) selective outcome reporting, and (vii) other
sources of bias.Data extraction
For each eligible study, two of the authors independently
extracted all the relevant data. Disagreement was re-
solved by a discussion with the third reviewer. Whenever
necessary, we contacted the authors of the studies for
missing data or further information. The following data
were extracted: (1) demographic data of participants; (2)
indication for TKA; (3) wound infection (superficial or
deep), hematoma, wound dehiscence, limb swelling, bleed-
ing from the wound, and reoperation because of a wound-
healing complication; (4) postoperative blood transfusion,
decrease in hemoglobin or hematocrit, thromboembolic
complications, patient discomfort, and costs; (5) functional
outcomes such as time to regain mobility; and (6) any
other outcomes as mentioned in individual studies were
considered for inclusion. In studies in which data were
incomplete or unclear, attempts were made to contact in-
vestigators for clarification.Data analysis and statistical methods
The meta-analysis was undertaken using RevMan 5.1 for
Windows (The Cochrane Collaboration, Oxford, United
Kingdom). We assessed statistical heterogeneity for each
study with the use of a standard chi-square test (for het-
erogeneity, a level of P < 0.1 was considered significant)
and the I2 statistic. An I2 statistic value of 50% was con-
sidered to indicate substantial heterogeneity. The origins
of heterogeneity, if present, were analyzed according to
differences in methodological quality, characteristics of
participants, and intervention. When the data allowed,
the authors of this paper performed subgroup analysis of
the trials. In comparing trials showing heterogeneity,
pooled data were meta-analyzed using a random-effects
model. Otherwise, a fixed-effects model was used for the
analysis. Relative risks (or risk differences) and 95% con-
fidence intervals (CIs) were calculated for dichotomous
Figure 3 Forest plot diagram showing the effect of Floseal® on drainage volume.
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We identified a total of 189 citations as potentially rele-
vant. By screening the title and reading the abstract and
the entire article, we found that three RCTs and two
non-RCTs enrolling a total of 766 knees at a final
follow-up were eligible for data extraction and meta-
analysis [9-13]. The patients’ characteristics were pre-
sented in Table 1. The sample size for each study
ranged from 20 to 349. Jadad scale is used to evaluate
the quality of RCTs while MINORS assessment is used
for non-RCTs. The quality of the literature is relatively
high. But there are still some methodological limita-
tions in RCTs. All the RCTs [9-11] reported that
randomization was conducted through a computer-
assisted program. A double-blind methodology was re-
ported in two RCTs [10,11]. None of the RCTs suggest
a methodology for the blinding assessors. All of the
studies provided results for a minimum of 95% of the
included patients. Most of the patients who managed to
undergo primary TKA suffered from osteoarthritis. Kim
and Comadoll [11,13] reported that all TKA were ac-
complished by the same doctor. Cemented prosthesis
was used in four studies [10-13]. The other one used anFigure 4 Forest plot diagram showing the effect of Floseal® on drainauncemented prosthesis. Electrocautery hemostasis com-
bined with a thrombin-based hemostatic agent was used
in the treatment group in all the studies except one [12]
which used an agent only. The control group received
electrocautery hemostasis. Four literatures [9-12] men-
tioned volume of drainage in 24 h postoperatively. None
of the studies reported whether drainage was clamped or
not, while two studies [10,11] stated the size and number
of the drainage tube. Tourniquets were used in all the in-
clusive patients and were deflated after wound closure in
three studies [9-11] and before wound closure in Coma-
doll’s study. Helito did not provide this information
while the pressure of the tourniquet was recorded
(300 mmHg) [12]. Two studies [10,11] applied bandage
after wound closure. Spinal anesthesia was performed
in the study of Kim and Helito [11,12]. Others did not
mention an anesthesia method. The dosage of Floseal®
ranged from 10 to 20 ml, 10 ml in three studies [9-11]
and 20 ml in Comadoll’s trial. None of the studies used
placebo in a control group. Four studies [9,10,12,13]
provided the indications of blood transfusion, which
based on postoperative hemoglobin level, signs and
symptoms of anemia such as hypotension, paleness,
and tachycardia. Perioperative antithromboembolic
prophylaxis therapy was performed in all the patients
as followed in Table 1. The duration of a follow-up
ranged from discharge to 6 weeks.ge volume on the need for transfusion.
Figure 5 Forest plot diagram showing the effect of Floseal® on drainage volume total blood loss.
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Hemoglobin decline
We obtained usable data on hemoglobin drop from four
trials including 566 knees [9,10,12,13]. As depicted in
Figure 2, there was significant heterogeneity (χ2 = 17.02,
df = 3, I2 = 82%, P = 0.0007). Using a random-effects
model, the pooled results indicated that there was signifi-
cant difference between the groups in terms of hemoglobin
drop (MD= −0.65, 95% CI: −0.96 to −0.34, P <0.0001). Sub-
group analysis was performed for postoperative hemoglobin
decline which showed that the existence of heterogeneity
was due to the different doses of Floseal® and duration of
drainage (Table 2).Volume of drainage
The volume of drainage was mentioned in four trials
[9-12]. The pooled results showed significant heterogen-
eity (χ2 = 151.02, df = 3, I2 = 95%, P < 0.00001; Figure 3).
Thus, a random-effects model was used. Meta-analysis
showed no significant difference between the groups in
terms of volume of drainage (MD = −179.98, 95%
CI: −454.01 to 94.06, P = 0.20).Need for transfusion
The need for transfusion was reported in four trials
[9,10,12,13]. The pooled results showed no significant
difference between the groups (RR = 0.69, 95% CI: 0.18
to 2.63, P = 0.05). There was significant heterogeneity
(χ2 = 7.95, df = 3, I2 = 62%, P =0.05; Figure 4). A random-
effects model was used.Figure 6 Forest plot diagram showing the effect of Floseal® on the inTotal blood loss
Total blood loss was documented in two studies [9,10].
The difference between the groups was significant
(MD = −290.14, 95% CI: −458.83 to −121.44, P = 0.0007;
Figure 5). A random-effects model was used because
statistical heterogeneity was found between the studies
(χ2 = 3.62, df = 1, I2 = 72%, P = 0.06).
Infection
The incidence of infection was reported in three studies
[9,11,13]. The pooled results indicated that the incidence
of infection was 0.6% in the Floseal® group, compared
with 0.13% in the conventional group. This difference
was not significant (RD = −0.01, 95% CI: −0.02 to 0.01,
P = 0.45; Figure 6). A fixed-effects model was used be-
cause no statistical heterogeneity was found between the
studies (χ2 = 2.67, df = 2, I2 = 25%, P = 0.26).
Deep vein thrombosis (DVT)
The incidence of DVT was reported in three trials
[9,11,13]. The pooled results of the trials showed that
the use of Floseal® did not increase the risk of DVT.
(RD = 0.00, 95% CI: −0.01 to 0.02, P = 0.67). There was
no significant heterogeneity (χ2 = 0.64, df = 2, I2 = 0%,
P =0.73; Figure 7). A fixed-effects model was used.
Pulmonary embolism (PE)
The incidence of PE was mentioned in two trials [9,13]. The
pooled results of the trials showed that the use of Floseal®
did not increase the risk of DVT. (RD= 0.00, 95% CI: −0.01
to 0.02, P = 0. 59). There was no significant heterogeneitycidence of infection.
Figure 7 Forest plot diagram showing the effect of Floseal® on the incidence of DVT.
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model was used.
Other outcomes
Several other outcome measures were identified, but in-
sufficient data were provided for meta-analysis. For in-
stance, Suarez found no significant differences in overall
length of stay, hematocrit values, and postoperative
fluids or hidden blood loss between two study groups
[10]. There were no significant differences in colloid and
crystalloid infusion between two groups in the study of
Helito [12].
Discussion
The most important finding of the present meta-analysis
was that the use of thrombin-based hemostatic agents
can decrease the postoperative hemoglobin drop and
total blood loss. Furthermore, no significant differences
were found regarding to the risk of wound infection,
DVT, and PE.
Three RCTs, one PCT, and one CCT met the inclusion
criteria for the meta-analysis. All the RCTs stated that
randomization was achieved by a computer-assisted pro-
gram. The overall methodological quality of the included
studies was relatively high. Two RCTs [10,11] reported a
methodology of double-blind, and no studies were pro-
vided to blind the assessors of group allocation so ex-
pectation bias and the potential for type II statistical
error in their clinical outcomes may affect the analysis.
All included studies had consistent baseline data, but
none of them mentioned intention to treat analysis.Figure 8 Forest plot diagram showing the effect of Floseal® on the inThese methodological strengths and weaknesses should
be considered when interpreting the findings of the
present meta-analysis.
TKA is complicated by perioperative blood loss; 7.7%–
18.93% of the patients undertaking TKA need transfusion
[14-17]. The present meta-analysis indicated that there
was no significant difference in the rate of transfusion be-
tween two groups (6.98% vs 6.32%). The reason could be
an unmentioned transfusion trigger in the literature, dif-
ferent approach, and type of anesthesia in the surgical pro-
cedure. Besides various baselines of a preoperative
hemoglobin level, different dosage and kinds of antithrom-
botic drugs between two groups also should be taken into
consideration.
Four studies [9-12] mentioned postoperative volume
of drainage. Our studies found no statistically significant
differences between the treatment and control groups.
Some literatures [12,13] did not provide the time of
drainage discharge or the number of drainage tubes.
What is more, varied methods of anesthesia and surgical
approach may also affect the meta-analysis.
Anemia may lead to hypotension, cardiac failure, and
even shock. Blood transfusion was needed to correct
severe anemia. Four studies [9,10,12,13] reported a post-
operative hemoglobin decline. Two literatures [9,10]
mentioned total blood loss. The present meta-analysis
showed significant differences in postoperative hemoglobin
decline and total blood loss. Subgroup analysis showed the
source heterogeneity for postoperative hemoglobin decline
(Table 2). Extravasation into the tissues is the major hidden
postoperative blood loss. While apparent postoperativecidence of PE.
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a present meta-analysis, we consider that the use of
thrombin-based hemostatic agents can reduce hemoglobin
drop and perioperative blood loss.
Infection is relatively rare after TKA but can be devas-
tating in terms of morbidity and cost [18]. This meta-
analysis found no significant difference in the incidence
of infection, which was 0.6% with treatments and 0.13%
in controls; the overall infection rate was 0.94%. The re-
ported incidence of infection after TKA ranged from 1%
to 3% [19]. Because infection may also occur later, an as-
sessment after a longer follow-up period may be required.
DVT is one of the common complications after TKA
which may cause PE and even death [20]. Antithrom-
boembolic prophylaxis therapy was adapted in all the in-
clusive patients, and there was no difference in the
incidence of DVT (0.6% vs 0.33%) or PE (0.43% vs 0%)
between the two groups.
There are several potential limitations of our meta-
analysis. (1) Only five reports were included, and their
sample sizes were relatively small, which may have af-
fected our conclusions. (2) The follow-up of patients in
some of the trials was unclear. Many patients were
followed up in the short term. This may have resulted in
underreporting of, for example, infection. (3) There were
insufficient data to support analyses of length of stay,
range of motion (ROM), postoperative fluids, and Visual
Analog Scale Pain Score. (4) The existence of a publica-
tion bias also affects the analysis; it is a limitation in all
meta-analysis. However, this is the first systematic re-
view to evaluate safety and efficiency of thrombin-based
hemostatic agents during TKA, by only including studies
that have appropriate control and study groups. All of
the included studies were of high quality. Further studies
should be designed to explore an optimal dose and add-
itional functions during the TKA based on high quality
RCTs.Conclusion
The present meta-analysis indicates that thrombin-based
hemostatic agents can reduce hemoglobin decline and
total blood loss after TKA and are not related to the ad-
verse reactions or complications such as wound infection,
DVT, and PE. In summary, the use of thrombin-based
hemostatic agents is superior to standard electrocautery in
patients undergoing primary TKA.
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